November 11, 2008
Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein
NEW ORLEANS, Nov. 11 /PRNewswire-USNewswire/ -- A lipid-lowering drug reduced heart attacks by 54 percent in people who had normal cholesterol but elevated levels of high sensitivity C-reactive protein (hsCRP), according to a study presented at the American Heart Association Scientific Sessions 2008. Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Men and Women with Elevated Levels of C-Reactive Protein: the JUPITER Trial was presented as a late-breaking clinical trial. The study was simultaneously published in the New England Journal of Medicine.
"Compared to those who received placebo, patients receiving the drug rosuvastatin also had a 48 percent reduction in stroke, a 46 percent reduction in the need for interventions to reopen blocked blood vessels and a 20 percent drop in all-cause mortality," said Paul M. Ridker, M.D., lead author of the study and director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, Boston, Mass.
Patients included in the trial were men over age 50 and women over age 60, with no history of cardiovascular disease (CVD), with LDL ("bad" cholesterol) levels 10 percent (10 percent to 20 percent indicates an intermediate risk level). While they had not had any cardiovascular event, those with a FRS >10 would be considered to be at higher risk for such events than a low risk or completely healthy population. More than 89,000 patients were screened to find the 17,802 who participated. Most of those excluded had either LDL levels that were too high or hsCRP levels that were too low.
Overall, compared to placebo-treated participants in the trial, those given rosuvastatin had a 44 percent reduction in the primary endpoint of a first major cardiovascular event -- a composite of heart attack, stroke, revascularization, hospitalization for unstable angina and cardiovascular death. Hospitalizations for cardiac reasons were also reduced and the authors suggested that the strategy tested in JUPITER of treating elevated hsCRP patients with statin therapy could be cost-effective.
Ridker said one particularly striking finding was a 37 percent reduction in first events in men and women in the statin group who had no other risk factors except for elevated hsCRP, a sign of inflammation that can be associated with increased coronary disease risk.
The researchers found no increase in the number of patients with either muscle pain or cancer among those given rosuvastatin. As in almost all prior statin trials, they observed a small increase in reported diabetes, said Ridker, the Eugene Braunwald Professor of Medicine at Harvard Medical School.
The very low LDL levels produced by rosuvastatin (median 54 at 24 months) raise the question of whether other adverse effects might be seen over a longer time period, but they were not evident here.
Low-density lipoprotein (LDL) is a component of total cholesterol thought to contribute to plaque buildups that narrow arteries, a process called atherosclerosis. JUPITER participants had average LDL levels of 108 milligrams per deciliter (mg/dL) at the study's start -- well below the 160 mg/dL level at which doctors normally consider beginning treatment with statins to lower cholesterol.
The study did not provide details as to how patients with hsCRP levels >10mg/L were handled. The 2003 consensus statement by the Centers for Disease Control and Prevention and the American Heart Association suggests that many elevations at those levels are due to transient inflammation from minor infections and that patients should have the test repeated to properly determine their chronic hsCRP level.
The 17,802 participants, recruited from 1,300 clinical sites in 26 countries, were randomly assigned to 20 milligrams (mg) of rosuvastatin a day or a daily placebo. The study's independent data and safety monitoring board ended the trial in March 2008, more than two years ahead of schedule, when it determined that the study data indicated "unequivocal benefit of rosuvastatin" on coronary-related death and disability.
"Not only do we confirm that apparently healthy men and women with elevated hsCRP are at high risk of cardiovascular events, but we demonstrate that a simple therapy can reduce their risk of heart attack, stroke or cardiovascular death," Ridker said.
JUPITER included nearly 6,801 women and 5,119 members of minority groups in the randomized cohort.
"For the first time in a major statin prevention trial, we have clear evidence of benefits in women as well as men, in blacks and Hispanics as well as Caucasians, and perhaps most importantly, a substantial reduction in all-cause mortality," he said. "It appears hsCRP predicts high risk even when cholesterol is low."
However, that issue was not specifically tested in this study.
The benefits of rosuvastatin in people with elevated hsCRP extended across all subgroups evaluated, including those with low Framingham scores and those with LDL levels of less than 100mg/dL, Ridker said.
This is consistent with the earlier Heart Protection Study, a largely secondary prevention study where the benefit of a statin was similar at high and low levels of LDL cholesterol.
Diet, exercise and smoking cessation are all known to lower hsCRP levels and are first-line interventions recommended for the general population to reduce the risk of heart attack and stroke. However, until now, no large, prospective data study has shown that any pharmacologic therapy given to those without elevated cholesterol levels but with elevated hsCRP could prevent cardiovascular events.
Since statins lower both LDL cholesterol and hsCRP (used as a marker of inflammation), the findings presented at the meeting cannot determine whether cholesterol lowering, a reduction in inflammation, or a combination of both are responsible for the reductions seen.
Other co-authors are: Eleanor Danielson, B.A.; Francisco Fonseco, M.D.; Jacques Genest, M.D.; Antonio M. Gotto, M.D.; John J.P. Kastelein, M.D., Ph.D.; Wolfgang Koenig, M.D.; Peter Libby, M.D.; Alberto Lorenzatti, M.D.; Jean MacFadyen, B.A.; Borge G. Nordestgaard, M.D.; James Shepherd, M.D.; James T. Willerson, M.D.; and Robert J. Glynn, Ph.D. Individual author disclosures are available on the abstract.
The study was sponsored by AstraZeneca.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.americanheart.org/corporatefunding.
American Heart Association
CONTACT: AHA News Media Staff Office at the Ernest N. Morial ConventionCenter, +1-504-670-6524
Web Site: http://www.americanheart.org/